Triple-negative breast cancer, defined clinically as lacking estrogen receptor (ER) and progesterone receptor (PgR) expression as well as human epidermal growth factor receptor 2 (HER2) gene amplification, represents up to 20% of all breast cancers and is associated with a more aggressive clinical course compared to other breast cancer subtypes1,2. The gene discussed is ESR1; the disease is breast cancer.